Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Tangram Therapeutics PLC
Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine
March 5, 2026